Authors
Latest:
The Key to Better Navigating VUCA Industry ConditionsAlison Horstmeyer discusses how pharma executives can apply four attributes of curiosity to negotiate VUCA (volatile, uncertain, complex, and ambiguous) conditions and improve organizational outcomes.
Latest:
Does the Pfizer Restructuring Make Sense?The Pfizer restructuring will be a case study in whether corporate restructuring & innovation can co-exist or whether M&A is the more viable answer, writes Edward Pratesi.
Latest:
Five Measures to Cope with the Side Effects of Health ReformWith more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before.
Latest:
Pharma AI Requires a New Approach to GovernanceArtificial intelligence adoption by pharma companies in the UK demands a new, agile governance layer, write Tim Wright and Antony Bott.
Latest:
Optimizing the Digital Opportunity in Biopharmaceutical R&DIf advanced technologies hold the key to at least some of the productivity issues R&D organizations need to overcome, Nicholas Lakin asks what are the best strategies and operating models for exploiting these aids to their fullest potential.
Latest:
Hitting Your Targets: A Check-up on DataProvider data delivers insights into customers and drives decisions about where to focus resources, providing opportunities for sales and marketing in life sciences.
Latest:
3 Cash-Saving Hacks for the Pharmaceutical IndustryA list of four ways the pharma industry can save money on travel-related employee expenses regarding VAT on clinical trials, clinical trial supplies, sourcing, and more.
Latest:
Hitting Your Targets: A Check-up on DataProvider data delivers insights into customers and drives decisions about where to focus resources, providing opportunities for sales and marketing in life sciences.
Latest:
Cross-Border Funding in the Life SciencesRecord capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.
Latest:
‘Emerging’ Product Launch StrategiesCommercial leaders can boost product launches with a data-driven roadmap.
Latest:
What Issues Are Top of Mind for Smaller Biotech and Emerging Biopharma Companies?Daniel Patrick discusses the small biotech company journey from an incubator of ideas to the ability to shepherd an R&D asset through its pipeline to achieving commercial success.
Latest:
Linguistic Validation: Amplifying the Patient VoiceDesigning and managing clinical outcome assessments on an international basis is more than a translation task. It requires the more discrete practice of linguistic validation, writes Dana Weiss.
Latest:
Leading Courageously and Bringing Others Along In an Evolving Healthcare EnvironmentTo be successful, healthcare organizations must delve into optimizing leadership skills and building a deep pipeline of executive-ready talent.
Latest:
CEO Spills the Secret to Attracting, Retaining Biotech TalentOne of the most important jobs of a biotech executive is building a strong team that will not only keep a company competitive in the current market, but will also have the stamina to carry it into the future.
Latest:
3 Tips for Successful Public-Private Partnerships in HealthcareA list of three key elements when looking at public-private partnerships to tackle public health challenges.
Latest:
Army Leadership Lessons: Develop Leaders Three Levels DownChad Storlie draws on military training to outline how all industries and organisations can create great junior leaders.
Latest:
Emerging Collaboration in EU Drug Pricing and Reimbursement: A Beneluxa Case StudyMaude Schmidt and Giovanni Saldutti look at the intergovernmental initiatives involving joint price negotiations developed across Europe as the Beneluxa Initiative on Pharmaceutical Policy to explore the outcomes and implications from these alliances.
Latest:
AI and Benefit Verification: Providing Faster Access to MedicinesBenefit verification (BV) provides a detailed understanding of out of pocket costs for the prescribed treatment. Amy Jones details how AI is aiding the BV process.
Latest:
Enabling a Single Integrated View of Critical Real-World Data with Analytics as a ServiceAnalytics as a service can provide critical accelerators for the commercial transformation program at a life sciences organization, writes Himanshu Jain.
Latest:
What Natural Language Processing Can Do for Pharmacos: 3 Real-World Use CasesMany real-world data sources contain unstructured text, making it difficult and time-consuming to glean actionable insights from the data. Natural language processing technology can alleviate this problem, writes Jane Z. Reed.
Latest:
Navigating the Increasing Complexity of Drug-Biomarker Co-DevelopmentTo succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.
Latest:
Improving Management of Gene and Cell TherapiesAn overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Latest:
Improving Management of Gene and Cell TherapiesAn overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Latest:
Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and PatientsUpcoming regulatory changes to create new opportunity for specialized offerings.
Latest:
Improving Management of Gene and Cell TherapiesAn overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Latest:
Improving Management of Gene and Cell TherapiesAn overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Latest:
Five Features to Ensure Lab-ready BuildingsA list of five essential features a building must have in order to be considered lab-ready.
Latest:
The ‘Spare-No-Expense’ AlternativeHow low-cost drugs can succeed in the specialty pharmacy channel.
